Krystal Biotech (KRYS) Total Current Liabilities (2016 - 2026)

Krystal Biotech has reported Total Current Liabilities for 11 years, with the latest figure at $127.4 million in Q2 2026.

• Total Current Liabilities for Q2 2026 came in at $127.4 million, up 46.61% year-over-year; the trailing twelve-month figure through Jun 2026 was $127.4 million (up 46.61% YoY), and the FY2025 annual result was $102.9 million, up 0.93% from the prior year.
• Total Current Liabilities rose to $127.4 million in Q2 2026, from $107.8 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $127.4 million in Q2 2026 and troughed at $23.9 million in Q2 2023.
• A 5-year average of $65.5 million and a median of $66.1 million in 2022 frame the typical range for Total Current Liabilities.
• The widest annual swing landed in 2022, when Total Current Liabilities surged 560.95%; it then tumbled 41.96% in 2023.
• A 5-year view of Total Current Liabilities shows it stood at $28.8 million in 2022, then grew by 14.72% to $33.1 million in 2023, then jumped by 208.2% to $102.0 million in 2024, then increased by 0.93% to $102.9 million in 2025, then increased by 23.76% to $127.4 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $127.4 million in Q2 2026, $107.8 million in Q1 2026, and $102.9 million in Q4 2025.